Gastrointestinal Drugs in Pharmacology

Learning Objectives

By the end of this topic, you should be able to:

• Explain the mechanism of action of antacids, H2 receptor antagonists, and proton pump inhibitors (PPIs), and rank them by acid-suppression potency.
• Describe how PPIs work at the molecular level and why they must be given before meals.
• List the drugs used in triple therapy for H. pylori eradication and explain why acid suppression alone fails to cure peptic ulcers caused by the organism.
• Classify antiemetics by their receptor target (5-HT3, D2, H1, NK1) and match each class to its best clinical use.
• Differentiate bulk-forming, osmotic, and stimulant laxatives by mechanism, onset of action, and safety profile.
• Recognize the major adverse effects and drug interactions of the most commonly prescribed GI drug classes.

Quick Answer

Gastrointestinal drugs treat acid-related disease, motility disorders, nausea, constipation, diarrhea, and inflammatory bowel disease. The acid-suppressing drugs form a clear hierarchy: antacids neutralize acid already secreted (fast but brief), H2 blockers reduce acid secretion by blocking histamine signaling (moderate, several hours), and PPIs irreversibly shut down the final common pathway of acid secretion — the H+/K+ ATPase pump — giving the strongest and longest-lasting suppression. Antiemetics are chosen by cause: 5-HT3 antagonists (ondansetron) for chemotherapy-induced vomiting, D2 antagonists (metoclopramide) for gastroparesis, and antihistamines/anticholinergics for motion sickness. Laxatives range from gentle bulk-forming fiber to fast-acting stimulants, chosen based on how quickly relief is needed and how much bowel stimulation is appropriate. Getting the mechanism right for each class is what lets you predict both efficacy and side effects on exams.

Core Content

1. Antacids

Mechanism of Action Antacids are weak bases that directly neutralize hydrochloric acid already present in the stomach lumen, raising gastric pH. They do not reduce acid production — they mop up acid that has already been secreted. This is why their relief is fast (minutes) but short-lived (1–3 hours), and why they are used for symptom relief rather than healing.

• Aluminum hydroxide — constipating (slows gut motility)
• Magnesium hydroxide — causes diarrhea (osmotic effect)
• Calcium carbonate (Tums) — fast-acting, but can cause acid rebound and hypercalcemia with chronic overuse
• Combination products (e.g., Maalox = magnesium + aluminum hydroxide) are formulated to cancel out each other's bowel effects.

Indications: Heartburn, indigestion, mild GERD, as an adjunct for immediate symptom relief while a PPI or H2 blocker takes effect.

Key interaction: Antacids raise gastric and urinary pH and chelate cations, reducing the absorption of many drugs (tetracyclines, fluoroquinolones, iron, levothyroxine). Always separate dosing by at least 2 hours.

2. H2 Receptor Antagonists

Mechanism of Action Parietal cells secrete acid through three converging stimuli: histamine (via H2 receptors), gastrin, and acetylcholine. H2 blockers competitively block the histamine H2 receptor on the basolateral membrane of the parietal cell, reducing acid secretion by roughly 60–70%, mainly the acid stimulated by food and nocturnal secretion.

Examples: Famotidine (Pepcid), Ranitidine (Zantac — largely withdrawn worldwide since 2020 due to NDMA contamination; do not list it as first-line anymore), Cimetidine (Tagamet — strong CYP450 inhibitor, causes gynecomastia with chronic use).

Indications: GERD, peptic ulcer disease, prevention of stress ulcers in ICU patients, Zollinger-Ellison syndrome (adjunct).

Limitation students often miss: Tolerance develops within days to weeks of continuous use (tachyphylaxis), which is one reason PPIs have largely replaced H2 blockers for long-term acid suppression.

3. Proton Pump Inhibitors (PPIs)

Mechanism of Action PPIs are prodrugs. In the acidic environment of the parietal cell's secretory canaliculus, they become protonated and convert to their active sulfenamide form, which then forms an irreversible covalent bond with cysteine residues on the H+/K+ ATPase ("proton pump") — the final common step of acid secretion, regardless of what stimulated it (histamine, gastrin, or acetylcholine). Because the bond is irreversible, acid secretion only resumes once the parietal cell synthesizes new pump molecules, which takes roughly 24–48 hours — this is why PPIs give the deepest and longest acid suppression of any class.

Why timing matters: PPIs only bind pumps that are actively secreting acid, which happens after a meal stimulates the parietal cell. Taking a PPI on an empty stomach 30–60 minutes before breakfast maximizes the number of active pumps available for binding — a classic exam point.

Examples: Omeprazole, Esomeprazole, Pantoprazole, Lansoprazole, Rabeprazole.

Indications: GERD, erosive esophagitis, peptic ulcer healing, Zollinger-Ellison syndrome, NSAID-induced ulcer prevention, and as one arm of H. pylori eradication therapy.

H. pylori eradication (classic triple therapy): PPI + Clarithromycin + Amoxicillin (or Metronidazole if penicillin-allergic) for 10–14 days. Acid suppression alone will heal the ulcer temporarily, but without eradicating H. pylori the ulcer recurs — this is a frequently tested concept.

Long-term risks: Increased risk of C. difficile infection, community-acquired pneumonia, hypomagnesemia, vitamin B12 deficiency, and osteoporotic fractures with prolonged use — because gastric acid is needed for absorption of B12 and calcium, and normally acts as a barrier against ingested pathogens.

4. Prokinetics

Mechanism of Action These drugs increase GI motility by enhancing coordinated smooth muscle contraction, generally through dopamine (D2) receptor antagonism in the gut (which normally inhibits motility) or through 5-HT4 receptor agonism.

Examples: Metoclopramide (D2 antagonist; also crosses the blood-brain barrier, causing extrapyramidal side effects and, with chronic use, tardive dyskinesia), Domperidone (peripheral D2 antagonist, doesn't cross the BBB well, so fewer CNS effects but prolongs QT interval).

Indications: Gastroparesis (especially diabetic gastroparesis), GERD unresponsive to acid suppression alone, and as an antiemetic (see below).

5. Laxatives

Laxatives are grouped by how they work — this determines both onset of action and appropriate clinical use.

Type	Mechanism	Onset	Examples
Bulk-forming	Absorb water, increase stool mass, mechanically stimulate peristalsis	1–3 days	Psyllium (Metamucil), Methylcellulose
Osmotic	Draw water into the colon by osmosis, softening and increasing stool volume	6–48 hours (PEG faster, lactulose slower)	Polyethylene glycol (MiraLAX), Lactulose, Magnesium hydroxide
Stimulant	Directly irritate the colonic mucosa and enteric nerves, increasing motility	6–12 hours	Bisacodyl (Dulcolax), Senna
Stool softener	Lower stool surface tension, allowing water to penetrate	1–3 days	Docusate sodium

Clinical pearl: Bulk-forming agents are first-line for chronic, simple constipation because they are physiologic and safest for long-term use. Stimulant laxatives work fast but are not meant for daily long-term use because of concerns about dependence and electrolyte loss. Lactulose has a bonus use in hepatic encephalopathy — it acidifies the colon, trapping ammonia as ammonium ion and flushing it out.

6. Antidiarrheal Agents

Mechanism of Action: Loperamide acts on opioid mu-receptors in the gut wall to slow motility without significant CNS penetration (so no abuse potential at normal doses). Bismuth subsalicylate has antisecretory, antimicrobial, and anti-inflammatory effects.

Indications: Acute non-infectious diarrhea, traveler's diarrhea, IBS with diarrhea predominance. Caution: Avoid antimotility agents in suspected invasive bacterial diarrhea (bloody stool, fever) — slowing transit can worsen toxin absorption and prolong illness (e.g., in C. difficile colitis or Shiga-toxin-producing E. coli).

7. Antiemetics

Antiemetics are best learned by their receptor target, because the target tells you the clinical situation they're used for.

Class	Receptor Blocked	Best Use	Example
5-HT3 antagonists	Serotonin (5-HT3) in the gut and chemoreceptor trigger zone (CTZ)	Chemotherapy-induced and post-operative nausea/vomiting	Ondansetron
D2 antagonists	Dopamine in the CTZ	Chemotherapy, gastroparesis-related nausea	Metoclopramide, Prochlorperazine
NK1 antagonists	Substance P (neurokinin-1) in the CTZ	Delayed/severe chemotherapy-induced vomiting, given with a 5-HT3 blocker	Aprepitant
H1 antagonists / anticholinergics	Histamine / muscarinic receptors in the vestibular pathway	Motion sickness, vertigo	Meclizine, Scopolamine

Mechanism detail on ondansetron: It blocks 5-HT3 receptors both peripherally (on vagal afferents in the gut, which release serotonin when chemotherapy damages enterochromaffin cells) and centrally in the CTZ — it does not sedate or cause extrapyramidal effects like the dopamine antagonists, which is why it is now first-line for chemo-induced nausea. Its main risk is QT prolongation at high doses.

8. 5-Aminosalicylic Acids (5-ASA), Immunosuppressants, and Biologics (IBD therapy)

These form a step-up ladder for inflammatory bowel disease severity:

1. 5-ASA compounds (Mesalamine) — reduce mucosal inflammation topically in the gut, mainstay for mild-to-moderate ulcerative colitis.
2. Immunosuppressants (Azathioprine, Methotrexate) — used when 5-ASA fails or to maintain remission, especially in Crohn's disease; onset is slow (weeks to months).
3. Biologics (Infliximab, Adalimumab — anti-TNF-alpha) — reserved for moderate-to-severe disease or when conventional therapy fails; fast-acting but carry infection risk (screen for latent TB before starting).

Visual: Acid Suppression Hierarchy

Key Terms

Term	Definition
Parietal cell	Gastric mucosal cell that secretes HCl via the H+/K+ ATPase pump; the shared target of PPIs and, indirectly, H2 blockers
H+/K+ ATPase	The "proton pump" on parietal cells that exchanges intracellular H+ for extracellular K+, the final common step of acid secretion, irreversibly blocked by PPIs
Tachyphylaxis	Rapid decline in drug response with repeated dosing over a short period; seen with H2 blockers within days
Chemoreceptor trigger zone (CTZ)	Area postrema of the medulla, outside the blood-brain barrier, that detects circulating toxins/drugs and triggers vomiting; target of most antiemetics
Triple therapy	PPI + two antibiotics (typically clarithromycin + amoxicillin) used to eradicate H. pylori and cure peptic ulcer disease
Osmotic laxative	A laxative that pulls water into the bowel lumen by osmotic gradient rather than by stimulating nerves
5-ASA	Mesalamine and related compounds that deliver anti-inflammatory action topically to inflamed bowel mucosa in IBD
Anti-TNF biologic	Monoclonal antibody that neutralizes tumor necrosis factor-alpha, a key inflammatory cytokine in Crohn's disease and ulcerative colitis

Common Mistakes

Misconception 1: "PPIs and H2 blockers work the same way, just with different strength." Why it's wrong: They act on completely different steps of the acid-secretion pathway. H2 blockers only block one of three inputs (histamine) to the parietal cell, so gastrin and acetylcholine can still drive some acid secretion. PPIs block the final shared pump itself, downstream of all three inputs. Correct understanding: This is exactly why PPIs suppress acid more completely and for longer — they don't just dampen one signal, they disable the pump the signals were trying to activate.

Misconception 2: "Acid suppression alone cures peptic ulcers caused by H. pylori." Why it's wrong: Acid suppression lets the ulcer heal temporarily by removing the acid that was preventing mucosal repair, but it does not touch the bacterium causing the underlying damage. Correct understanding: Without antibiotic eradication (triple therapy), H. pylori persists and the ulcer recurs after the drug is stopped — eradication, not just suppression, is curative.

Misconception 3: "All antiemetics are interchangeable — any one will stop any kind of vomiting." Why it's wrong: Nausea and vomiting are triggered through different receptor pathways depending on the cause (chemotherapy releases serotonin from gut cells; motion sickness activates the vestibular system via histamine/muscarinic pathways). Correct understanding: Matching the antiemetic to the trigger matters — a 5-HT3 antagonist like ondansetron is excellent for chemotherapy-induced vomiting but does little for motion sickness, which responds better to antihistamines like meclizine.

Comparison and Connections

Feature	Antacids	H2 Blockers	PPIs
Site of action	Gastric lumen (neutralizes acid)	H2 receptor on parietal cell	H+/K+ ATPase pump on parietal cell
Onset	Minutes	30–60 minutes	Hours (full effect after days of dosing)
Duration	1–3 hours	~6–10 hours	24+ hours (irreversible until new pumps made)
Tolerance with chronic use	No	Yes (tachyphylaxis)	No
Best use	Quick symptom relief	Moderate, intermittent acid control	Ulcer healing, GERD, H. pylori regimens

Feature	Metoclopramide	Ondansetron
Receptor	D2 antagonist (also 5-HT4 agonist at gut)	5-HT3 antagonist
CNS penetration	Yes — risk of extrapyramidal symptoms, tardive dyskinesia	Minimal sedation, no EPS
Extra benefit	Also a prokinetic (helps gastroparesis)	No motility effect
Main use	Gastroparesis, general nausea	Chemotherapy/post-op nausea

Practice Questions

Recall

1. What enzyme do proton pump inhibitors inhibit, and where is it located? Answer guidance: The H+/K+ ATPase ("proton pump") on the apical membrane of gastric parietal cells.
2. Name the three antibiotics/drug classes used in standard triple therapy for H. pylori. Answer guidance: A PPI plus two antibiotics — typically clarithromycin and amoxicillin (or metronidazole if penicillin-allergic).

Understanding 3. Explain why PPIs must be dosed before meals rather than at any time of day. Answer guidance: PPIs only covalently bind proton pumps that are actively secreting acid; a meal stimulates parietal cells to activate their pumps, so taking the drug 30–60 minutes before eating maximizes the number of pumps available to be irreversibly blocked. 4. Why does tolerance develop with H2 blockers but not with PPIs? Answer guidance: H2 blockers reversibly and competitively occupy the H2 receptor, and the parietal cell can compensate over days via receptor upregulation or by relying more on gastrin/acetylcholine pathways — this is tachyphylaxis. PPIs act irreversibly downstream of all three stimulatory pathways, so there's no compensatory route around the blockade.

Application 5. A patient with confirmed H. pylori-positive duodenal ulcer is treated with omeprazole alone for 8 weeks. Symptoms resolve, then recur 2 months later. What went wrong? Answer guidance: Omeprazole allowed the ulcer to heal by suppressing acid, but without antibiotics H. pylori was never eradicated, so it continued to damage the mucosa and the ulcer recurred. The patient needed triple therapy. 6. A patient develops involuntary lip-smacking and grimacing after months of metoclopramide use for gastroparesis. What is happening, and why? Answer guidance: This is tardive dyskinesia, caused by metoclopramide's chronic central D2 receptor blockade (it crosses the blood-brain barrier), the same mechanism responsible for antipsychotic-induced movement disorders.

Analysis 7. Compare why calcium carbonate antacids can cause "acid rebound" while PPIs do not. Answer guidance: Neutralizing acid raises antral pH, which removes negative feedback on gastrin release, causing a rebound surge in acid secretion once the antacid wears off. PPIs prevent acid secretion at the pump itself, so there is no equivalent rebound stimulus generated by neutralization — though abrupt PPI discontinuation after long-term use can cause a different rebound from parietal cell hyperplasia/gastrin elevation. 8. A patient on chronic omeprazole for 5 years presents with a hip fracture after minimal trauma and new-onset paresthesias. Which two PPI-associated deficiencies should be considered, and why do they occur? Answer guidance: Hypomagnesemia (impaired intestinal magnesium absorption, contributing to paresthesias/tetany) and reduced calcium absorption/bone density from chronic hypochlorhydria (acid is needed to solubilize calcium salts and vitamin B12-intrinsic factor complexes), raising fracture risk.

FAQ

Q1: Why are PPIs considered stronger than H2 blockers if both "reduce stomach acid"? Because they act at different points in the pathway. H2 blockers only interrupt the histamine signal reaching the parietal cell, while PPIs disable the pump itself — the shared final step no matter what triggered acid release. Blocking the endpoint is inherently more complete than blocking one upstream input.

Q2: Is it safe to take an antacid and a PPI at the same time? Generally yes for occasional breakthrough symptoms, but they should be spaced apart because a sudden pH change from an antacid can interfere with the acidic environment PPIs need to convert to their active form. Routine co-use isn't usually necessary once a PPI is at steady state.

Q3: Why was ranitidine pulled from the market? Ranitidine formulations were found to degrade over time (and under heat) into NDMA, a probable human carcinogen, prompting recalls starting in 2019–2020. Famotidine is the preferred H2 blocker alternative today.

Q4: Why does metoclopramide cause movement disorders but ondansetron doesn't? Metoclopramide blocks dopamine D2 receptors centrally, and dopamine blockade in the basal ganglia produces extrapyramidal symptoms — the same mechanism seen with antipsychotics. Ondansetron works on serotonin 5-HT3 receptors, a pathway not linked to motor control, so it lacks this side effect.

Q5: Are stimulant laxatives dangerous for daily long-term use? They aren't inherently dangerous for short courses, but chronic daily use raises concerns about electrolyte disturbances (particularly hypokalemia) and a debated "cathartic colon" effect from long-term nerve stimulation. Bulk-forming agents are preferred for long-term, everyday management of constipation.

Quick Revision

• Antacids neutralize existing acid (fast, brief); H2 blockers reduce acid secretion via histamine blockade (moderate, tolerance develops); PPIs irreversibly block the H+/K+ ATPase (strongest, longest).
• PPIs must be taken 30–60 minutes before a meal to catch actively secreting pumps.
• Triple therapy for H. pylori = PPI + Clarithromycin + Amoxicillin (or Metronidazole if penicillin-allergic), 10–14 days.
• Acid suppression heals ulcers temporarily; only H. pylori eradication prevents recurrence.
• Chronic PPI use risks: hypomagnesemia, B12 deficiency, fractures, C. diff infection, pneumonia.
• Ranitidine was withdrawn due to NDMA contamination; famotidine is the safer H2 blocker choice.
• Antiemetics are matched to mechanism: 5-HT3 antagonists (ondansetron) for chemo/post-op nausea, D2 antagonists (metoclopramide) for gastroparesis, NK1 antagonists (aprepitant) for delayed chemo nausea, antihistamines (meclizine) for motion sickness.
• Metoclopramide crosses the blood-brain barrier and can cause extrapyramidal symptoms/tardive dyskinesia with chronic use.
• Laxative choice depends on speed needed: bulk-forming (days, safest long-term) < osmotic (hours) < stimulant (hours, fastest but not for daily chronic use).
• Lactulose has a dual role: osmotic laxative and treatment for hepatic encephalopathy (traps ammonia in the colon).
• IBD therapy follows a step-up ladder: 5-ASA → immunosuppressants → anti-TNF biologics, based on severity.
• Avoid antimotility antidiarrheals (loperamide) in bloody or febrile diarrhea suggestive of invasive infection.

Related Topics

Prerequisites

• Basic gastric physiology (parietal, chief, and G cells; acid secretion pathways)
• Autonomic pharmacology (cholinergic and histaminergic receptor signaling)
• General pharmacokinetics (prodrugs, enzyme inhibition, half-life vs. duration of action)

Related Topics

• Peptic Ulcer Disease and H. pylori pathophysiology (Gastroenterology/Medicine)
• Antimicrobial Pharmacology (for triple/quadruple therapy antibiotic choices)
• Chemotherapy-Induced Nausea and Vomiting management (Oncology)
• Inflammatory Bowel Disease pathology (Crohn's disease vs. ulcerative colitis)

Next Topics

• Hepatobiliary Drugs in Pharmacology
• Antimicrobial Agents in Pharmacology
• Drugs Used in Chemotherapy-Associated Toxicity Management